Bausch Health Companies Inc.
BHCHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeBausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. The $2.40B market capitalization puts BHC squarely in mid-cap range for its industry. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Market Cap
$2.40B
Beta
0.37
P/E (TTM)
—
P/E (Fwd)
1.53
EPS (TTM)
$-2.94
EPS (Fwd)
$4.19
ROE
—
ROA
6.6%
Cash
$1.82B
Total Debt
$20.78B
Free CF
$1.43B
52W Change
-8.3%
Annual Financials
Cash vs Debt
Where BHC stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, BHC finished 14.34% above its 150-day moving average ($5.51) and 7.69% above its 200-day moving average ($5.85). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BHC overbought or oversold?
At the August 28, 2026 close, BHC's RSI(14) was 51.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Bausch Health Companies Inc. carries $20.78B in total debt against $1.82B in cash reserves — debt is roughly 11.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $1.43B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. An ROA of 6.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $8.12B (2022) to $10.27B (2025), reflecting a 26% increase over the period.
With a beta below 0.7, Bausch Health Companies Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bausch Health Companies Inc. and its sector.